Latest News and Press Releases

G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights

Trilaciclib Reduces Hospitalizations and Myelosuppressive Events in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) and May Improve Survival

G1 Therapeutic's COSELA (trilaciclib) included in ASCO's updated SCLC treatment guidelines

G1 Therapeutics to release 3Q23 financial results on November 1, 2023

G1 to present four posters at the 2023 ASCO Quality Care Symposium

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Communications Officer Will...

RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...

- Recognized Total Revenue of $42.4 Million, Including $11.1 Million in Net COSELA® (trilaciclib) Revenue - - Reiterated Expectation for Interim Overall Survival (OS) Analysis of Pivotal Phase 3...

RESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it will participate in two August...

- Results Confirm that Trilaciclib Reduces Single and Multilineage Grade ≥3 Myelosuppressive Hematologic Adverse Events (HAEs) Including Neutropenia, Anemia, and Thrombocytopenia - - Analyses Showed...